文章基本信息

标题：Ustekinumab Treatment in Patients with Moderate-to-Severe Psoriasis and Latent Tuberculosis Infection: A Study of 3 Case Reports
本地全文：下载
作者：Waqas S. Abdulwahhab ; Alaa S. Mehair ; Al Shayma F. Iedi 等
期刊名称：Journal of Cosmetics, Dermatological Sciences and Applications
印刷版ISSN：2161-4105
电子版ISSN：2161-4512
出版年度：2022
卷号：12
期号：2
页码：95-99
DOI：10.4236/jcdsa.2022.122008
语种：English
出版社：Scientific Research Pub
摘要：Background: Ustekinumab is a human monoclonal antibody that binds to the shared P40 subunit of interleukin (IL)-12 and IL-23 and is approved for the treatment of moderate-to-severe psoriasis. Latent tuberculosis (LTBI) was diagnosed based on a positive tuberculin skin test (TST) or QuantiFERON-TB test without evidence of active tuberculosis (TB). Aim: To evaluate the risk of active tuberculosis reinfection in patients with a history of psoriasis and LTBI after INH prophylaxis treated with Ustekinumab. Case Report: We are describing 3 patients with a history of moderate-to-severe plaque psoriasis and newly identified LTBI who have been treated with INH monotherapy before starting Ustekinumab therapy followed-up over 2 years for any sign of tuberculosis reinfection. Conclusion: Ustekinumab is an option for treating psoriasis and LTBI with minimal risk of reactivation after INH prophylaxis.
关键词：PsoriasisUstekinumabLatent TuberculosisQuantiFERON-TB Test